openPR Logo
Press release

Diabetic Retinopathy Market Size in the 7MM is anticipated to grow by 2032 | DelveInsight

04-22-2024 08:20 PM CET | Health & Medicine

Press release from: ABNewswire

Diabetic Retinopathy Market Size in the 7MM is anticipated

DelveInsight's 'Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Diabetic retinopathy, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Takeaways from the Diabetic Retinopathy Market Research Report

* The increase in Diabetic Retinopathy Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Diabetic Retinopathy Market is anticipated to witness growth at a considerable CAGR.
* According to secondary research by analysts at DelveInsight, it is estimated that the prevalence of DR is slightly higher in males as compared to females.
* The leading Diabetic Retinopathy Companies working in the market include Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others
* Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include OTT166, MS-R001 (rapamycin), Runcaciguat (BAY1101042), Intravitreal Ranibizumab 0.5 mg Injection, and others.
* April 2024: Bayer - A Phase 2 Randomized, Placebo-controlled, Double-masked Proof-of-concept Study to Investigate the Efficacy and Safety of Runcaciguat (BAY 1101042) in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy. This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint.
* April 2024:- Greater Houston Retina Research- Faricimab for Retinal Non-Perfusion Associated With Non-Proliferative Diabetic Retinopathy: The MAGIC Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial. The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.

Discover which therapies are expected to grab the Diabetic Retinopathy Market Share @ Diabetic Retinopathy Market Outlook [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Retinopathy Overview

Diabetic retinopathy is a diabetes-related complication that affects the eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). In the initial stages, it might not cause any noticeable symptoms, but as it progresses, it can lead to vision problems and even blindness if left untreated. High blood sugar levels associated with diabetes can damage the tiny blood vessels in the retina, leading to swelling, leakage, or abnormal growth of blood vessels. Regular eye exams are crucial for people with diabetes to detect and manage diabetic retinopathy early.

Diabetic Retinopathy Epidemiology Insights

The epidemiology section of Diabetic Retinopathy offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Diabetic Retinopathy Epidemiology trends @ Diabetic Retinopathy Epidemiological Insights [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Retinopathy Drugs Market

The Diabetic Retinopathy Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Diabetic Retinopathy signaling in Diabetic Retinopathy are likely to uncover new therapeutic targets and further expand treatment options for patients.

Diabetic Retinopathy Treatment Market Landscape

The Diabetic Retinopathy treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Diabetic Retinopathy has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To know more about Diabetic Retinopathy treatment guidelines, visit @ Diabetic Retinopathy Treatment Market Landscape [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Retinopathy Market Outlook

The report's outlook on the Diabetic Retinopathy market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Diabetic Retinopathy therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Diabetic Retinopathy drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Diabetic Retinopathy market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Diabetic Retinopathy Drugs Uptake

The drug chapter of the Diabetic Retinopathy report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Diabetic Retinopathy.

Major Diabetic Retinopathy Companies

Several Diabetic Retinopathy Companies working in the market include Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others

Learn more about the FDA-approved drugs for Diabetic Retinopathy @ Drugs for Diabetic Retinopathy Treatment [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Diabetic Retinopathy Market Research Report

* Coverage- 7MM
* Diabetic Retinopathy Companies- Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others
* Diabetic Retinopathy Pipeline Therapies- OTT166, MS-R001 (rapamycin), Runcaciguat (BAY1101042), Intravitreal Ranibizumab 0.5 mg Injection, and others.
* Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy Market Drivers and Barriers
* Diabetic Retinopathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Diabetic Retinopathy Drugs in development @ Diabetic Retinopathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Diabetic Retinopathy Market Overview at a Glance

4. Executive Summary of Diabetic Retinopathy

5. Disease Background and Overview

6. Management and Treatment

7. Epidemiology and Patient Population

8. Patient Journey 1

9. Patient Journey 2

10. Marketed Drugs

11. Emerging Drugs

12. Other Therapy

13. Diabetic Retinopathy: Seven Major Market Analysis

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-retinopathy-market-size-in-the-7mm-is-anticipated-to-grow-by-2032-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diabetic Retinopathy Market Size in the 7MM is anticipated to grow by 2032 | DelveInsight here

News-ID: 3472189 • Views:

More Releases from ABNewswire

Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance Repair with Extended Service Hours
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients. Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue Massage Approach
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief. Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shortage
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access. The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair Launches 24/7 Emergency Response
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise. Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical

All 5 Releases


More Releases for Diabetic

Rising Diabetic Population Fuels Growth In The Diabetic Footwear Market Emerges …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Diabetic Footwear Market Through 2025? The size of the market for diabetic footwear has seen significant expansion in the past few years. From $8.45 billion in 2024, it is set to increase to $9.2 billion in 2025, exhibiting a compound annual growth
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report. On the basis of
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282 Global Diabetic Socks Market: Factors Impacting the Market The primary factors driving the growth of the global diabetic socks market are increasing
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be